pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,897 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1164Endpoints878BioPharma Dive339BioSpace298Fierce Biotech278onclive165raps104globenewswire health73
therapy area
allOncology7438Rare Disease1839Cardiology1679Immunology1467Hematology1303Vaccines1190Pulmonology
  • Otsuka showcases kidney drug data; Pfizer cuts an AI deal
    Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off gen…
    BioPharma Dive · 3mo agoDealNeutral↗ source
  • Elevance Health’s chief digital officer discusses practical AI applications for insurers
    Elevance Health interviewed its chief digital information officer, Ratnakar Lavu, about how health insurers are adopting artificial intelligence. Lavu, who previously held digital roles at Kohl’s,…
    Endpoints · 3mo agoNeutral↗ source
← prev
page 62 of 76
next →
fda recalls67
fda medwatch60
fda press38
1092
Psychiatry & CNS862
Ophthalmology494
Pain473
Endocrinology & Metabolism466
Infectious Disease444
  • Axsome secures settlement to keep Sunosi exclusive until 2040
    Axsome Therapeutics announced it has reached a settlement that pushes back the entry of generic versions of its narcolepsy medication Sunosi until 2040. The agreement was reached with the last rem…
    Endpoints · 3mo agoRegulatoryPositive↗ source
  • Bipartisan House bill would require security review of U.S. biotech investments in China
    A bipartisan group of Representatives introduced legislation on Tuesday that would expand the Committee on Investment and National Security (COINS) Act to cover biotechnology. The bill, called the…
    BioPharma Dive · 3mo agoRegulatoryNeutral↗ source
  • Eli Lilly partners with Ascidian Therapeutics on $1.9 b RNA exon-editing collaboration for kidney disease
    Eli Lilly and Boston-based Ascidian Therapeutics announced a research collaboration aimed at discovering medicines for genetically driven kidney diseases. The partnership leverages Ascidian’s RNA e…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • NewLimit raises $435M Series C to launch epigenetic anti-aging therapy, while Lilly signs GLP-2 obesity drug deal
    Longevity startup NewLimit announced a $435 million Series C financing, one of the largest biotech rounds this year. The round was led by Founders Fund and included investors such as Thrive Capital…
    BioPharma Dive · 3mo agoNeutral↗ source
  • Regeneron expands partnership with CytomX as other pharma partners exit
    Regeneron announced it will deepen its collaboration with CytomX Therapeutics, a Bay Area biotech. The decision follows CytomX losing several partnership agreements with other large pharmaceutical…
    Endpoints · 3mo agoDealPositive↗ source
  • Eli Lilly signs up to $1.9B deal with Ascidian Therapeutics for RNA editing in kidney disease
    Ascidian Therapeutics recently presented early data indicating that its novel RNA‑editing approach to repair faulty genes appears safe in humans, focusing on kidney disease applications. Eli Lilly…
    Endpoints · 3mo agoDealPositive↗ source
  • Alnylam commits $30 million upfront to AI startup Inceptive for RNA research collaboration
    Alnylam Pharmaceuticals announced a new collaboration with Inceptive, a Silicon Valley biotech startup that focuses on RNA. The agreement includes an upfront payment of $30 million and is intended…
    Endpoints · 3mo agoDealPositive↗ source
  • Eli Lilly says its GLP-1 weight loss shot and pill now covered for millions of Americans
    Eli Lilly announced that its GLP-1 based weight-loss injection and oral medication have been added to the formularies of the three largest pharmacy benefit managers. The company said this move make…
    Endpoints · 3mo agoPositive↗ source
  • Mineralys Therapeutics raises funds ahead of pending lorundrostat hypertension approval
    Mineralys Therapeutics first came to market attention in 2021 when it licensed a novel hypertension candidate, lorundrostat, from Japan’s Tanabe Pharma, agreeing to a modest $1 million upfront paym…
    Endpoints · 3mo agoDealNeutral↗ source
  • FDA issues new guidance for pharma on discussing unapproved drugs with payors
    The FDA has released guidance aimed at biopharma companies that are preparing to launch new therapies before they receive formal approval. The advice focuses on how companies can inform health-pla…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Legend surges on early data for ‘in vivo’ lymphoma cell therapy
    Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.
    BioPharma Dive · 3mo agoRegulatoryNeutral↗ source
  • Bristol Myers Squibb assesses AI spending after deploying tools to thousands of staff
    Bristol Myers Squibb has recently provided artificial intelligence applications to a large portion of its workforce. The company is now turning its attention to measuring the cost of these tools a…
    Endpoints · 3mo agoNeutral↗ source
  • Roche reports narrow failure of breast cancer pill in Phase 3 trial at ASCO
    Roche updated investors and the oncology community that its experimental breast cancer oral therapy did not meet its primary endpoint in a pivotal Phase 3 study. The data, presented at the America…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Fulcrum Therapeutics considers sale after FDA blocks sickle cell drug development
    Fulcrum Therapeutics announced it is undertaking a strategic review that could lead to a sale after its lead sickle cell candidate, pociredir, was effectively blocked by the FDA. The agency cited…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source
  • AbiVax shares plunge as safety concerns shadow strong ulcerative colitis trial results
    AbiVax reported Phase 3 data for its experimental therapy obefazimod in patients with moderately to severely active ulcerative colitis. Two dose levels achieved placebo‑adjusted clinical remission…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • ASCO 2026 Highlights Bispecific Antibodies, ADCs and New Advances in RAS-Targeted and Prostate Cancer Therapies
    The meeting featured a lively comparison of bispecific antibodies and antibody-drug conjugates as leading modalities in oncology. Researchers presented data suggesting that targeting mutant RAS pr…
    BioPharma Dive · 3mo agoPositive↗ source
  • Allen Institute launches multi-hundred-million-dollar effort to turn brain atlas data into neurodegenerative drug candidates
    The Allen Institute, a Seattle nonprofit known for basic brain research, announced a major new effort to move its brain‑atlas knowledge toward drug development. The program will invest several hun…
    Endpoints · 3mo agoPositive↗ source
  • Celcuity's gedatolisib trial cuts death risk but misses investor expectations
    Celcuity reported data from its Phase 3 VIKTORIA-1 trial evaluating gedatolisib in HR‑positive, HER2‑negative breast cancer with PIK3CA mutations. The trial enrolled 350 patients who had progresse…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • FDA issues draft guidance outlining data flexibilities for cell and gene therapy developers
    The FDA released a draft guidance from its Center for Biologics Evaluation and Research (CBER) that clarifies how developers of cell and gene therapies can use existing data and prior knowledge in…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • NewLimit secures $435M funding, valuation tops $3B, aims for human trials in 2027
    NewLimit, a Bay Area anti-aging biotech, announced a financing round that raised $435 million, valuing the company at more than $3 billion. The round is among the largest private biotech financing…
    Endpoints · 3mo agoDealPositive↗ source
  • Eli Lilly gives 340B hospitals a week to share data or lose drug discounts
    Eli Lilly has told hospitals and medical groups that participate in the 340B drug discount program that they must submit claims data for all Lilly medications by the coming Monday, or they will be…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source
  • Contraline secures $92.5M Series B to fund Phase 3 trial of male contraceptive gel
    Contraline, a startup developing a male contraceptive, announced it has closed a Series B financing round worth $92.5 million. The capital will be used to advance its candidate, referred to as NES…
    Endpoints · 3mo agoDealPositive↗ source
  • Travere Therapeutics pays $112 million upfront to China’s Everest Medicines to expand rare kidney disease pipeline
    Travere Therapeutics, a San Diego‑based biotech, announced a partnership with China‑based Everest Medicines to strengthen its rare kidney disease portfolio beyond its approved drug Filspari. Under…
    Endpoints · 3mo agoDealPositive↗ source